Emerging therapeutic targets and agents for glioblastoma migrating cells

Area of Science:

• Neuro-oncology
• Cancer Biology
• Molecular Medicine

Background:

• Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumor with a poor prognosis, often diagnosed late.
• Despite aggressive multimodal treatments including surgery, radiotherapy, and chemotherapy, patient survival remains limited to 12-14 months.
• Tumor cell migration beyond surgical margins into healthy brain tissue is a primary reason for treatment failure.

Purpose of the Study:

• This review focuses on novel therapeutic targets and agents aimed at inhibiting glioma cell migration in GBM.
• The objective is to explore strategies to overcome treatment resistance driven by invasive tumor cells.
• To highlight the importance of understanding and controlling GBM cell motility for future therapeutic advancements.

Main Methods:

• This is a review article, synthesizing current research on GBM cell migration.
• Literature search conducted on emerging targets and therapeutic agents impacting glioma cell motility.
• Analysis of preclinical and clinical data related to anti-migratory strategies in GBM.

Main Results:

• Several molecular pathways and targets involved in GBM cell migration have been identified.
• Emerging therapeutic agents show promise in preclinical models for inhibiting glioma cell invasion.
• Targeting cell migration represents a promising strategy to improve the efficacy of existing GBM treatments.

Conclusions:

• Inhibiting glioblastoma cell migration is a critical therapeutic goal for improving patient outcomes.
• Further research into novel anti-migratory agents and combination therapies is warranted.
• Controlling tumor cell invasion is essential for developing more effective treatments for GBM.